NMN vs Rapamycin
Moderate Research vs FDA Approved
compatible Researched · 90% Rapamycin (mTOR inhibitor) and NMN (NAD+ precursor) target distinct but complementary aging pathways. Rapamycin modulates mTOR-driven growth signaling while NMN supports NAD+-dependent repair and energy metabolism. No known negative interactions. Some longevity researchers use both as part of comprehensive anti-aging protocols.
Molecular Data
NMN Rapamycin
Weight 334.22 Da 914.17 Da
Half-life ~2-3 hours (oral) ~62 hours
Type Nucleotide (C11H15N2O8P) Macrolide lactone (C51H79NO13)
Key Benefits
NMN
01 Increases blood and tissue NAD+ levels, counteracting age-related decline
02 Supports mitochondrial function and cellular energy production
03 Activates sirtuin pathways involved in DNA repair and longevity
04 May improve insulin sensitivity and glucose metabolism
05 Supports cardiovascular function and vascular health
06 May enhance exercise capacity and muscle endurance
07 Promotes healthy aging at the cellular level
08 Supports cognitive function and neuroprotection
Rapamycin
01 Lifespan extension demonstrated in every model organism tested (yeast, worms, flies, mice)
02 Upregulation of autophagy and cellular quality control mechanisms
03 Reduction of senescent cell burden and associated inflammatory secretome
04 Improved immune function at low pulsed doses (paradoxical immune enhancement)
05 Reduced age-related inflammation (inflammaging) via mTORC1 inhibition
06 Enhanced mitochondrial function and biogenesis
07 Potential reduction in age-related cancer risk through growth pathway suppression
08 Improved vaccine response in elderly populations at low intermittent doses
Side Effects
NMN
Mild gastrointestinal discomfort (nausea, bloating, diarrhea) at higher doses
Flushing or warmth, particularly at doses above 500 mg
Mild headache during initial supplementation period
Increased energy that may affect sleep if taken too late in the day
Rapamycin
Mouth sores / aphthous ulcers (most common, usually dose-dependent and self-limiting)
Mild lipid changes (elevated LDL cholesterol and triglycerides)
Temporary glucose elevation or mildly impaired fasting glucose
Mild gastrointestinal discomfort (nausea, loose stools)
Skin changes (mild acne, slower wound healing at injection/cut sites)
Contraindications
Known hypersensitivity to nicotinamide mononucleotide or related compounds
Active cancer (theoretical concern: NAD+ supports rapidly dividing cells; consult oncologist)
Pregnancy or breastfeeding (insufficient safety data)
Severe hepatic impairment (altered NAD+ metabolism)
Active serious infection or immunocompromised state
Hypersensitivity to rapamycin/sirolimus or any macrolide compound
Severe hepatic impairment (rapamycin is extensively hepatically metabolized)
Planned major surgery within 2-4 weeks (impaired wound healing)
Pregnancy or breastfeeding
Concurrent use of strong CYP3A4 inhibitors without dose adjustment (ketoconazole, itraconazole, clarithromycin, grapefruit juice)
Research Evidence
NMN Rapamycin
Status Moderate Research FDA Approved
References 5 studies 5 studies
Latest April 2021 March 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.